Market closed
Contineum Therapeutics/$CTNM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Contineum Therapeutics
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.
Ticker
$CTNM
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
41
Website
CTNM Metrics
BasicAdvanced
$114M
-
-$2.18
-
-
Price and volume
Market cap
$114M
52-week high
$22.00
52-week low
$3.85
Average daily volume
77K
Financial strength
Current ratio
20.693
Quick ratio
20.529
Long term debt to equity
2.427
Total debt to equity
3.16
Management effectiveness
Return on assets (TTM)
-18.53%
Return on equity (TTM)
-26.19%
Valuation
Price to book
0.58
Price to tangible book (TTM)
0.58
Price to free cash flow (TTM)
-2.558
Growth
Earnings per share change (TTM)
-2,805.97%
3-year earnings per share growth (CAGR)
-45.87%
What the Analysts think about CTNM
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Contineum Therapeutics stock.
CTNM Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
CTNM Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
CTNM News
AllArticlesVideos
Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors
Business Wire·1 month ago
Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones
Business Wire·2 months ago
Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Contineum Therapeutics stock?
Contineum Therapeutics (CTNM) has a market cap of $114M as of April 27, 2025.
What is the P/E ratio for Contineum Therapeutics stock?
The price to earnings (P/E) ratio for Contineum Therapeutics (CTNM) stock is 0 as of April 27, 2025.
Does Contineum Therapeutics stock pay dividends?
No, Contineum Therapeutics (CTNM) stock does not pay dividends to its shareholders as of April 27, 2025.
When is the next Contineum Therapeutics dividend payment date?
Contineum Therapeutics (CTNM) stock does not pay dividends to its shareholders.
What is the beta indicator for Contineum Therapeutics?
Contineum Therapeutics (CTNM) does not currently have a Beta indicator.